Wojtukiewicz M Z, Zacharski L R, Memoli V A, Kisiel W, Kudryk B J, Rousseau S M, Stump D C
Department of Medicine, Dartmouth Medical School, Vermont.
Anticancer Res. 1990 May-Jun;10(3):579-82.
The mechanism of coagulation activation in renal cell carcinoma was investigated using immunohistochemical techniques applied to fresh frozen sections of resected primary tumors. Tissue factor antigen was detected in the endothelium of vascular channels within the tumors. Fibrinogen and factor V were distributed diffusely in the perivascular tumor connective tissue. Fibrin was readily detected in a linear pattern along the edges of nodules of viable tumor indicating that thrombin had formed from the interaction of coagulation factors demonstrated previously in renal cell carcinoma tissue. Tissue plasminogen activator was detected in the endothelium of blood vessels in the vicinity of the tumor and urokinase in areas of necrosis but neither were associated with viable tumor cells. These results indicate that thrombin is formed locally in renal cell carcinoma tissue that transforms fibrinogen to fibrin. There also appears to be a net deficit in fibrinolysis in situ in this tumor. We postulate that these conditions might contribute to stabilization and progression of renal cell carcinoma and that clinical trials of antithrombotic agents are justified in this tumor type.
采用免疫组化技术对切除的原发性肿瘤新鲜冰冻切片进行研究,以探讨肾细胞癌中凝血激活的机制。在肿瘤内血管通道的内皮中检测到组织因子抗原。纤维蛋白原和因子V弥漫分布于血管周围的肿瘤结缔组织中。在存活肿瘤结节边缘很容易检测到呈线性分布的纤维蛋白,这表明凝血酶是由先前在肾细胞癌组织中证实的凝血因子相互作用形成的。在肿瘤附近血管的内皮中检测到组织纤溶酶原激活物,在坏死区域检测到尿激酶,但两者均与存活的肿瘤细胞无关。这些结果表明,肾细胞癌组织中局部形成凝血酶,将纤维蛋白原转化为纤维蛋白。该肿瘤原位纤溶似乎也存在净缺陷。我们推测,这些情况可能有助于肾细胞癌的稳定和进展,并且抗血栓药物的临床试验在这种肿瘤类型中是合理的。